Kanya Rajangam
Chief Tech/Sci/R&D Officer bij SENTI BIOSCIENCES, INC.
Vermogen: 38 077 $ op 31-03-2024
Profiel
Dr. Kanya Rajangam is a Chief Medical & Development Officer at Senti Biosciences, Inc., an Independent Director at Turnstone Biologics Corp.
and an Independent Director at Turnstone Biologics, Inc. She is on the Board of Directors at Turnstone Biologics Corp.
and Turnstone Biologics, Inc. Dr. Rajangam was previously employed as a Chief Medical Officer by Nkarta, Inc., a Chief Medical Officer & Senior Vice President by Atara Biotherapeutics, Inc., a Chief Medical Officer by Cleave Biosciences, Inc., an Executive Director by Nektar Therapeutics, a Senior Medical Director by Onyx Pharmaceuticals, Inc., and an Associate Medical Director by Exelixis, Inc. She received her doctorate degree from Northwestern University and a doctorate degree from St. John's Medical College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SENTI BIOSCIENCES, INC.
0.22% | 01-02-2024 | 101 000 ( 0.22% ) | 38 077 $ | 31-03-2024 |
| 16-10-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Kanya Rajangam
| Bedrijven | Functie | Begin |
|---|---|---|
| SENTI BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01-07-2022 |
| TURNSTONE BIOLOGICS CORP. | Director/Board Member | 01-11-2021 |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Director/Board Member | 01-11-2011 |
Eerdere bekende functies van Kanya Rajangam
| Bedrijven | Functie | Einde |
|---|---|---|
| NKARTA, INC. | Chief Tech/Sci/R&D Officer | 05-06-2022 |
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-09-2018 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01-07-2017 |
| NEKTAR THERAPEUTICS | Director/Board Member | 01-05-2015 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 01-02-2015 |
Opleiding van Kanya Rajangam
| Northwestern University | Doctorate Degree |
| St. John's Medical College | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| EXELIXIS, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| SENTI BIOSCIENCES, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
